OVERACTIVE BLADDER SYNDROME: IS A REQUEST FOR A DOSE INCREASE INDICATIVE OF MORE SEVERE SYMPTOMS? RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RISFNG-DOSE STUDY OF SOLIFENACIN (SUNRISE) СтатьяCardozo L., Avdoshin V., Wolski Z., Pavlik I., Sofras F.E., Toth Z., Vasco P.M., Drogendijk T., Wright D.M., Bolodeoku J.INTERNATIONAL UROGYNECOLOGY JOURNAL. Том 18. 2007.